Elimination of lymphatic filariasis: do we have the drugs to complete the job?
about
A research agenda for helminth diseases of humans: towards control and eliminationCaspase dependent programmed cell death in developing embryos: a potential target for therapeutic intervention against pathogenic nematodesStructure of the trehalose-6-phosphate phosphatase from Brugia malayi reveals key design principles for anthelmintic drugsAnti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasisPopulation genetics of the filarial worm wuchereria bancrofti in a post-treatment region of Papua New Guinea: insights into diversity and life historyShort-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis.Possible changes in the transmissibility of trachoma following MDA and transmission reduction: implications for the GET2020 goals.Moxidectin and the avermectins: Consanguinity but not identity.Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis.Ocular onchocerciasis: current management and future prospectsTirandamycins from Streptomyces sp. 17944 inhibiting the parasite Brugia malayi asparagine tRNA synthetase.Multivalent vaccine formulation with BmVAL-1 and BmALT-2 confer significant protection against challenge infections with Brugia malayi in mice and jirds.In silico and in vitro studies on the protein-protein interactions between Brugia malayi immunomodulatory protein calreticulin and human C1q.The impact of two semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Republic of Congo.Unique structure and regulation of the nematode detoxification gene regulator, SKN-1: implications to understanding and controlling drug resistanceWill mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania.Ion channels and receptor as targets for the control of parasitic nematodes.Progress and challenges in the discovery of macrofilaricidal drugs.Future prospects and challenges of vaccines against filariasis.Overcoming the challenges of drug discovery for neglected tropical diseases: the A·WOL experience.The Impact of Nurses on Neglected Tropical Disease Management.Identification and prioritization of novel anti-Wolbachia chemotypes from screening a 10,000-compound diversity library.Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.Molecular cloning and characterization of glucose-6-phosphate dehydrogenase from Brugia malayi.Physicochemical properties of the modeled structure of astacin metalloprotease moulting enzyme NAS-36 and mapping the druggable allosteric space of Heamonchus contortus, Brugia malayi and Ceanorhabditis elegans via molecular dynamics simulation.Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs.Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment.Purification and characterization of guanylate kinase, a nucleoside monophosphate kinase of Brugia malayi.
P2860
Q21562257-D4F35A57-9A0B-4953-9E9B-AA1EA5185CC5Q27306040-72ABB820-6860-41A5-8701-2B28A0FEB90DQ27684540-049DAA23-BC6E-47A4-85DE-A4648D011821Q28294770-D35B8C5C-3AF4-4A27-B430-9FFC3EFA25B9Q28534623-BC8244C5-7204-4B80-AF44-A74068F28428Q30377066-D5F9CC66-2896-40BB-93E4-259FC7F5D3A3Q30670495-E7A01386-AF7A-4DFA-B5DB-5AFE6331C27EQ34404748-C4328FF2-1143-4442-B47D-10A669731C5BQ34454263-06D06409-F862-497A-8158-C69FD938AF83Q34633609-D3E13AA7-3CB9-4A79-9CBE-333DB8CB405EQ34778863-157A6EA5-2D65-4C65-B78A-7D48A1B12158Q35099033-B0D81739-392C-4EE2-B7C6-20A9705B266BQ35237370-8665169E-1E05-482E-8F57-AF409D1015E3Q35590790-F2163D7A-AA1C-4DA6-9D73-C9428F28D5F4Q36099627-08F05A40-F8CE-4D5B-A0D6-8AFECA2CF9AAQ36882744-2FBEA29D-B590-41B8-911D-E1B934CC0D0BQ37501925-596DE796-431B-4CC0-9BBB-740AF114CB14Q37912232-8BC1B74C-DF46-479F-99A0-2E1D23F27ABEQ37965765-4B9C7994-1D88-4D6E-A0A4-71DACDAD8815Q38163392-5F6AC5BF-1685-4616-87CB-036C9866EBB4Q38250382-5C893F74-373D-4B32-806B-ED6DB6FA4C12Q41678406-AF92BEEB-07C9-4DC3-B596-B3B50611ECB6Q42284546-F3FEAF77-4AED-4417-95CF-A2825B6B4C8EQ44458513-C7455EB3-502D-4BCF-8D5B-B95AB7DAA56EQ44995563-9AE83B14-9388-414D-B085-316A867BF5EBQ47553077-EE1AEF70-8F82-4578-9270-7DDD5A96815CQ50058050-46E70F60-CBAE-484F-919C-B902A144B73BQ54335111-B4533E11-6636-479A-94CC-989A2B1A8D9E
P2860
Elimination of lymphatic filariasis: do we have the drugs to complete the job?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Elimination of lymphatic filariasis: do we have the drugs to complete the job?
@en
Elimination of lymphatic filariasis: do we have the drugs to complete the job?
@nl
type
label
Elimination of lymphatic filariasis: do we have the drugs to complete the job?
@en
Elimination of lymphatic filariasis: do we have the drugs to complete the job?
@nl
prefLabel
Elimination of lymphatic filariasis: do we have the drugs to complete the job?
@en
Elimination of lymphatic filariasis: do we have the drugs to complete the job?
@nl
P1476
Elimination of lymphatic filariasis: do we have the drugs to complete the job?
@en
P2093
Moses J Bockarie
Rinki M Deb
P304
P356
10.1097/QCO.0B013E32833FDEE5
P577
2010-12-01T00:00:00Z